<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selective serotonin reuptake inhibitor poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selective serotonin reuptake inhibitor poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Selective serotonin reuptake inhibitor poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alicia B Minns, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evan Schwarz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Selective serotonin reuptake inhibitors (SSRIs) were introduced in the late 1980s for the treatment of depression. They are generally much safer in overdose than tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Commonly used SSRIs include <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>.</p><p>In 2017, an SSRI was mentioned in 57,254 single-substance toxic exposures reported to United States poison centers, 167 major outcomes, and only five fatalities [<a href="#rid1">1</a>]. The incidence of SSRI ingestions has steadily increased and mirrors the increase in SSRI prescriptions [<a href="#rid2">2</a>]. Isolated SSRI ingestions generally produce mild symptoms, although SSRI intoxication can infrequently produce serotonin toxicity, seizures, central nervous system (CNS) depression, or various cardiac abnormalities. <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> are structurally different from the other SSRIs and potentially more toxic in overdose.</p><p>The toxicity and management of acute SSRI overdose will be discussed here. A summary table to facilitate emergency management of SSRI poisoning is provided  (<a class="graphic graphic_table graphicRef82567" href="/d/graphic/82567.html" rel="external">table 1</a>). Discussions of the therapeutic use of these medications and of serotonin syndrome are found elsewhere. (See  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span><span class="headingEndMark"> — </span>Serotonin is produced from tryptophan, while <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> and dopamine are produced from tyrosine, through similar chemical pathways in nerve terminals. These neurotransmitters are stored in cytoplasmic vesicles of presynaptic neurons and released into the synapse with nerve depolarization. Transport proteins specific for serotonin, norepinephrine, or dopamine are embedded in the presynaptic terminal cell membrane and are responsible for pumping these neurotransmitters out of the synapse and back into the cytoplasm. Once in the cytoplasm, the neurotransmitters are either repackaged into vesicles for reuse or degraded by monoamine oxidase. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Pharmacology'</a>.)</p><p>Approximately 98 percent of the body's serotonin is found outside the central nervous system (CNS). The majority of serotonin is synthesized and stored in the enterochromaffin cells of the gut, where it induces contraction of gastrointestinal smooth muscle. There are at least seven families of 5-HT receptors (5-HT1 to 5-HT7), some of which have multiple subtypes [<a href="#rid3">3</a>]. In the CNS, serotonergic neurons are found in the brainstem, mostly in the raphe nucleus. They have a role in regulating mood, personality, appetite, wakefulness, emesis, temperature regulation, and sexual behavior [<a href="#rid4">4</a>]. Peripherally, serotonin aids in regulating vascular tone, peristalsis, and platelet activation.</p><p>Selective serotonin reuptake inhibitors (SSRIs) inhibit the reuptake mechanism of serotonin in CNS neurons, as well as peripherally and in platelets, thereby increasing the stimulation of serotonin receptors. Compared with tricyclic antidepressants (TCAs) and other antidepressants, SSRIs are less effective at blocking reuptake of <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> and likely less able to antagonize muscarinic, histaminergic, and adrenergic receptors.</p><p class="headingAnchor" id="H3"><span class="h1">KINETICS</span><span class="headingEndMark"> — </span>Selective serotonin reuptake inhibitors (SSRIs) are rapidly absorbed and reach a peak serum concentration within six hours  (<a class="graphic graphic_table graphicRef67511" href="/d/graphic/67511.html" rel="external">table 2</a>). Most SSRIs demonstrate a high degree of serum protein binding, and most have a long elimination half-life, with sustained biological activity due to active metabolites. <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> and <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> are unusual in that they have no active metabolites. In overdose, SSRI elimination times are further prolonged by the saturation of metabolic enzymes and by delayed absorption, especially for sustained-release preparations.</p><p>Due to <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>'s active metabolite norfluoxetine and to the slow elimination of both, significant accumulation of these drugs and delays in reaching a steady state can occur. Significant serum concentrations can persist even four to five weeks after discontinuation of fluoxetine [<a href="#rid5">5</a>]. This can result in adverse drug interactions and toxicity if a new antidepressant or serotonergic medication is introduced for up to a month after fluoxetine is stopped  (<a class="graphic graphic_table graphicRef67511" href="/d/graphic/67511.html" rel="external">table 2</a>).</p><p>All SSRIs are metabolized in the liver by the cytochrome P450 system; most metabolites are renally excreted.</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span></p><p class="headingAnchor" id="H5"><span class="h2">History</span><span class="headingEndMark"> — </span>Clinicians should seek answers to the following questions:</p><p class="bulletIndent1"><span class="glyph">●</span>Which drugs were ingested (including all coingestants and drug formulations, eg, sustained release)?</p><p class="bulletIndent1"><span class="glyph">●</span>What amount was ingested?</p><p class="bulletIndent1"><span class="glyph">●</span>When were the drugs ingested?</p><p></p><p>Every effort should be made to obtain this information, particularly if the patient is unable to provide a history due to alterations in mental status. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Initial evaluation and treatment'</a>.)</p><p>Patients with intentional ingestions often develop greater toxicity than those with accidental exposures, so it is important to ask the patient directly about his or her intentions. Information obtained from the overdose patient can be unreliable, and confirmation should be sought if available. Additional history, including comorbid conditions and signs and symptoms, should be elicited from the patient, family members, friends, emergency medical services (EMS) personnel, and police.</p><p class="headingAnchor" id="H6"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Examination begins with assessment and stabilization of the airway, breathing, and circulation. Next, the clinician should attempt to identify any possible toxidromes  (<a class="graphic graphic_table graphicRef71268" href="/d/graphic/71268.html" rel="external">table 3</a>). Key elements of the physical examination include vital signs, mental status, pupil size, skin dryness and color, and bowel sounds. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Initial evaluation and treatment'</a>.)</p><p>Clinicians should look specifically for evidence of serotonin toxicity, including hyperactive delirium with agitation, hyperthermia, diaphoresis, hypertonia, hyperreflexia, tremor, ankle clonus, and slow, continuous, horizontal eye movements (referred to as ocular clonus). Neuromuscular findings are generally more pronounced in the lower extremities [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Overview of SSRI toxicity</span><span class="headingEndMark"> — </span>Many studies comparing the ingestion of selective serotonin reuptake inhibitors (SSRIs) with other antidepressants have found that SSRIs rarely cause fatalities or serious sequelae [<a href="#rid6">6-10</a>]. SSRIs are significantly less toxic than tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). As an example, 31 to 32 percent of TCA ingestions require intubation compared with 4 to 6 percent of SSRI ingestions. Similarly, 31 to 35 percent of TCA ingestions require intensive care unit admission compared with 0 to 6 percent of SSRI ingestions [<a href="#rid6">6,8,11</a>]. One study found an incidence of 1.6 deaths per million SSRI prescriptions compared with 34.8 for TCAs and 20 for MAOIs [<a href="#rid10">10</a>].</p><p>It is also important to note the potential disparity in toxicity between SSRIs and serotonin and <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> reuptake inhibitors (SNRIs). SNRIs such as <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> have been associated with greater risk of significant toxicity and mortality in overdose. (See  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p>SSRIs (except for <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>) have a wide therapeutic window: ingestion of up to 30 times the daily dose typically produces minor or no symptoms, while ingestion of 50 to 75 times the daily dose can cause vomiting, mild central nervous system (CNS) depression, or tremor. Most fatalities are reported with either extremely large doses (greater than 150 times the daily dose) or with the presence of coingestants such as ethanol or benzodiazepines [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/333.html" rel="external">"Ethanol intoxication in adults"</a> and  <a class="medical medical_review" href="/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a>.)</p><p>Serotonin toxicity/syndrome rarely occurs after isolated SSRI ingestions. Serotonin toxicity caused by isolated SSRI ingestion tends not be severe, but severe episodes can occur following either a mixed serotonergic ingestion or changes made in therapeutic SSRI dosing. The term "serotonin toxicity" implies increased serotonergic activity in the central nervous system, which manifests as a spectrum of clinical findings often including mental status changes, autonomic hyperactivity, and neuromuscular abnormalities  (<a class="graphic graphic_algorithm graphicRef138424" href="/d/graphic/138424.html" rel="external">algorithm 1</a>). The term "serotonin syndrome" is also used to describe moderate to severe serotonin toxicity. Patients with SSRI overdose have a 10 to 14 percent incidence of serotonin toxicity, but many of these are mild presentations [<a href="#rid6">6,11</a>]. In a study of 469 isolated SSRI ingestions, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> were most likely to cause serotonin toxicity [<a href="#rid11">11</a>]. A full discussion of serotonin syndrome is found separately. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p>SSRI ingestions are unlikely to cause seizures or severe CNS depression [<a href="#rid6">6,11</a>]. Seizures have been noted to occur in 1 to 2 percent of SSRI overdoses, but they are typically short and self-limited [<a href="#rid11">11</a>]. However, based on United States poison center data, seizure is a relatively common consequence of isolated <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> overdose [<a href="#rid13">13</a>].</p><p>SSRIs do not have significant cardiotoxicity. Unlike the TCAs, they are typically not associated with QRS prolongation or ventricular dysrhythmias. In a review of 469 isolated SSRI ingestions, bradycardia occurred in 8 percent of cases and tachycardia in 15 percent [<a href="#rid11">11</a>]. <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a>, which is structurally unlike the other SSRIs, is the most cardiotoxic: ingestion is associated with prolongation of the corrected QT (QTc) interval, which can predispose a patient to torsade de pointes (see <a class="local">'Citalopram'</a> below).</p><p>Since SSRIs have little or no antagonism of muscarinic, histaminic, or adrenergic receptors, they do not typically cause anticholinergic symptoms, significant sedation, or hypotension.</p><p>In therapeutic dosing, SSRIs (specifically <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>) may cause hyponatremia, most likely via the syndrome of inappropriate antidiuretic hormone secretion (SIADH) [<a href="#rid14">14-16</a>]. Older adults appear to be at greatest risk of this complication. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">TOXICITY OF SPECIFIC AGENTS</span></p><p class="headingAnchor" id="H10"><span class="h2">Fluoxetine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> has been available longer than the other selective serotonin reuptake inhibitors (SSRIs), and many studies and reports exist supporting its safety in overdose [<a href="#rid12">12,17-20</a>]. Approximately half of fluoxetine ingestions remain asymptomatic, while the most frequently reported symptoms are nausea, vomiting, somnolence, tremor, agitation, and tachycardia. Most symptoms are benign and resolve quickly. Serious toxicity, such as dysrhythmias, seizures, central nervous system (CNS) depression, and respiratory arrest, is rare but can occur, especially when coingestants such as ethanol are present [<a href="#rid12">12,19</a>]. Serious toxicity is typically attributed to the coingestant and not to fluoxetine.</p><p>A prospective study assessing toxicity found <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> safer than tricyclic antidepressants (TCAs) [<a href="#rid21">21</a>]. Two deaths occurred out of 124 patients in the TCA group; no deaths occurred out of 16 patients in the fluoxetine group. Moreover, no fluoxetine patient developed seizures, QRS prolongation, hypotension, or serotonin toxicity; or required intubation. Mild CNS depression was seen in five of the fluoxetine overdoses.</p><p><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> overdose is well tolerated, even in very large amounts. Acute ingestions of 2 to 3 g typically cause only minimal symptoms [<a href="#rid18">18,22</a>]. There are several reports of death attributed to fluoxetine overdose, but they involved ingestions of 6 to 12 g [<a href="#rid23">23-25</a>]. Fluoxetine serum concentrations were 2300 to 6000 mcg/L in these patients, which is greater than most previously reported levels and significantly greater than the typical steady-state therapeutic concentration of 250 mcg/L. Fluoxetine has been associated with a 1 percent incidence of developing serotonin toxicity in isolated ingestion, but rarely are cases severe [<a href="#rid11">11</a>]. Most fatalities associated with fluoxetine overdose involve coingestants [<a href="#rid23">23</a>].</p><p>Case reports suggest that seizure should be considered a possible, albeit rare, complication of <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> overdose [<a href="#rid11">11,18,23,26-29</a>]. In two cases, the onset of seizure was delayed 9 to 16 hours after the ingestion [<a href="#rid27">27,29</a>]. However, in most cases, proconvulsant coingestants were either present or could not be excluded, and seizures tended to be brief and self-limited. During clinical trials, seizures rarely occurred in patients given therapeutic doses of fluoxetine [<a href="#rid18">18,30</a>]. In three prospective or cohort studies of fluoxetine ingestions, only four seizures were observed in a pooled sample of 325 patients [<a href="#rid11">11,19,21</a>].</p><p><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> has minimal cardiotoxicity. Prolongation of the corrected QT (QTc) interval of no greater than 450 msec was noted in 62 percent of fluoxetine overdose patients in one study, but none developed a ventricular dysrhythmia [<a href="#rid21">21</a>]. A prospective study of 32 fluoxetine ingestions found no electrocardiogram (ECG) abnormalities [<a href="#rid20">20</a>]. Rare reports exist of sinus bradycardia, supraventricular tachycardia, atrial fibrillation, atrial flutter, ST segment depression, and ventricular tachycardia associated with fluoxetine [<a href="#rid11">11,28,31-35</a>]. There is one report of QT prolongation to 600 msec and torsade de pointes requiring cardioversion in a 74-year-old woman three weeks after starting therapeutic fluoxetine [<a href="#rid36">36</a>]. In another report, a patient who ingested 2.4 g of fluoxetine developed a TCA-like QRS interval prolongation that responded to <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> administration [<a href="#rid29">29</a>]. A patient who ingested 12 g of fluoxetine developed bradycardia, which progressed to ventricular fibrillation and asystole [<a href="#rid23">23</a>]. Nevertheless, in both therapeutic use and overdose, fluoxetine-associated cardiotoxicity remains rare.</p><p class="headingAnchor" id="H11"><span class="h2">Sertraline</span><span class="headingEndMark"> — </span>Clinical trial and poison center data, various case reports, and several small studies suggest that <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> is as safe in overdose as <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> [<a href="#rid12">12,37-40</a>]. In a prospective poison center study of sertraline ingestions, 10 of 17 isolated overdoses had no signs or symptoms [<a href="#rid40">40</a>]. Another poison center study found that 34 out of 52 isolated sertraline ingestions were asymptomatic [<a href="#rid39">39</a>]. In these studies, the most common symptoms were nausea, tremor, and lethargy, while less common findings were agitation, vomiting, tachycardia, and bradycardia. Most symptoms resolved spontaneously within six hours [<a href="#rid39">39,40</a>]. Rare reports exist of brief, self-limited seizures and QTc prolongation [<a href="#rid11">11,12</a>]. Sertraline has been associated with a 20 percent incidence of developing serotonin toxicity in isolated ingestion, but rarely are cases severe [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Paroxetine</span><span class="headingEndMark"> — </span>As with the other SSRIs, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> is generally safe in overdose [<a href="#rid12">12,41</a>]. A poison center review noted that 8 out of 35 isolated paroxetine ingestions had no symptoms, while common symptoms included vomiting, drowsiness, tremors, dizziness, and sinus tachycardia [<a href="#rid42">42</a>]. Paroxetine has been associated rarely with brief, self-limited seizures and with an 18 percent incidence of developing serotonin toxicity in isolated ingestion, but rarely are cases severe [<a href="#rid11">11,12</a>].</p><p>Of note, among SSRIs, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> has the highest rate of discontinuation syndrome because of its short half-life and lack of active metabolites. Symptoms are usually mild, lasting one to two weeks; they include nausea, dizziness, bad dreams, paresthesia, and a flu-like illness. Severe symptoms can occur and persist for prolonged periods and may require restarting paroxetine [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/1716.html" rel="external">"Switching antidepressant medications in adults"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Fluvoxamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> is generally safe in overdose. In a poison center study of 299 fluvoxamine ingestions, toxicity was benign when the dose ingested was less than 1000 mg [<a href="#rid44">44</a>]. Common signs and symptoms of mild to moderate ingestions were drowsiness, tremor, diarrhea, vomiting, abdominal pain, dizziness, mydriasis, and sinus tachycardia. At higher doses, five seizures were reported, as well as deeper levels of sedation, hypokalemia, hypotension, sinus bradycardia (never requiring treatment), and repolarization disorders. Thirteen deaths were reported, but they could all be attributed to coingestants or other medical problems. Among the 55 patients in whom fluvoxamine was the sole ingestant, only mild to moderate symptoms were evident, and the authors concluded that isolated overdoses of fluvoxamine rarely cause severe toxicity. In another study, fluvoxamine was associated with brief, self-limited seizures and with a 17 percent incidence of developing serotonin toxicity in isolated ingestion [<a href="#rid11">11</a>]. Only rarely were these episodes of serotonin syndrome severe.</p><p><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> is associated with a discontinuation syndrome; symptoms can include dizziness, headache, nausea, and irritability [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/1716.html" rel="external">"Switching antidepressant medications in adults"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Citalopram</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> has the greatest potential for serious toxicity compared with other SSRIs. Citalopram is a racemic bicyclic phthalane derivative that is structurally different from the other SSRIs. It acts as a highly selective serotonin reuptake inhibitor but, unlike other SSRIs, also has antihistaminergic properties [<a href="#rid46">46</a>].</p><p>In <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> ingestions of less than 600 mg, symptoms tend to be mild and include nausea, dizziness, tachycardia, tremor, and somnolence [<a href="#rid47">47,48</a>]. With larger ingestions, citalopram can cause serious cardiac and neurologic toxicity. It has been associated with a 9 percent incidence of serotonin toxicity in isolated ingestion, but rarely are cases severe [<a href="#rid11">11</a>]. In rare instances, citalopram ingestions have been associated with metabolic acidosis [<a href="#rid49">49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiotoxicity</strong> — Anecdotal evidence and cohort analysis suggest that <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> is the most cardiotoxic SSRI. With moderate (approximately 600 mg) to large (approximately 1900 mg) ingestions, citalopram has been associated with a variety of cardiac conduction disturbances.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> is hepatically metabolized to desmethylcitalopram (DCT) and the likely cardiotoxic metabolite didesmethylcitalopram (DDCT). Animal studies have shown a correlation between high serum levels of DDCT and both prolonged QTc and death [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">In therapeutic dosing, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> has not been found to prolong the QTc interval, nor was there a relationship noted between DDCT concentration and the QTc interval [<a href="#rid51">51</a>]. However, in this study, the highest recorded serum DDCT concentration was approximately one-hundredth (1/100) of the levels measured in overdose patients who developed QTc prolongation [<a href="#rid52">52</a>]. Therefore, it is difficult to extrapolate these results to poisoned patients.</p><p></p><p class="bulletIndent1">A poison center review of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> ingestions in Swedish hospitals identified 44 cases without coingestants [<a href="#rid47">47</a>]. Of these, 6 of 18 patients who ingested greater than 600 mg developed a widened QRS complex, while all five patients who ingested greater than 1900 mg had either QRS widening, a seizure, or both. QRS changes were not seen immediately and resolved within 24 hours. None of the patients had a clinically significant dysrhythmia. A follow-up to this study included 108 cases, in which 25 percent of patients had either ST segment changes or widening of ECG intervals, but again, none had a clinically significant dysrhythmia [<a href="#rid48">48</a>]. Additional reviews have noted similar findings [<a href="#rid52">52,53</a>].</p><p></p><p class="bulletIndent1">In a logistic regression analysis of 57 <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> ingestions compared with 240 other SSRI ingestions, citalopram was five times more likely to prolong the QTc interval beyond 440 msec [<a href="#rid11">11</a>]. In the same study, the QTc was prolonged beyond 440 msec in 68 percent of cases and beyond 500 msec in 12 percent. QTc interval prolongation has been seen in patients who ingested as little as 400 mg [<a href="#rid54">54,55</a>]. In one of these reports, QTc prolongation was noted two hours after overdose, but it did not reach its peak until 13 hours [<a href="#rid54">54</a>]. There are multiple reports of citalopram ingestions and therapeutic dosing resulting in torsade de pointes [<a href="#rid56">56-62</a>]. In one of these reports, a patient developed intermittent torsades requiring intervention 36 hours after an ingestion of 1000 mg of citalopram [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1">Other cardiac changes noted with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> ingestions include left bundle branch block [<a href="#rid11">11,48,55,63</a>], right bundle branch block [<a href="#rid48">48</a>], ventricular extra beats [<a href="#rid47">47</a>], sinus bradycardia [<a href="#rid64">64</a>], sinus tachycardia [<a href="#rid52">52</a>], supraventricular tachycardia [<a href="#rid65">65</a>], ST segment changes [<a href="#rid47">47,52</a>], and several cases of ventricular fibrillation [<a href="#rid48">48,66</a>].</p><p></p><p class="bulletIndent1">The clinical significance of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>'s effects on cardiac conduction is unclear. Multiple fatalities have been attributed to overdoses of citalopram, but most involved coingestants [<a href="#rid12">12,46,67</a>]. In one report, a patient suffered a seizure and torsades de pointe and then expired from a pulseless electrical activity (PEA) arrest after an isolated citalopram ingestion [<a href="#rid62">62</a>]. Although citalopram ingestions can cause a wide range of cardiac disturbances, patients typically do well with minimal intervention. Most patients with QRS or QTc prolongation recover within 24 hours with either supportive care or with bicarbonate infusion (to treat QRS prolongation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurotoxicity</strong> — In clinical trials of therapeutic dosing, only 0.3 percent of patients treated with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> had a seizure, compared with 0.5 percent of patients taking placebo [<a href="#rid50">50</a>]. There are many reports, however, of citalopram ingestions causing seizures [<a href="#rid11">11,47,48,52,53,55,62,63,65</a>]. Although one head-to-head comparison suggested that seizures are no more likely following ingestions of citalopram versus other SSRIs [<a href="#rid11">11</a>], other reviews are contradictory and placed the incidence of citalopram-induced seizures at 6 to 14 percent [<a href="#rid48">48,53</a>]. Citalopram is a common cause of seizures in single-agent ingestions reported to poison centers [<a href="#rid13">13</a>]. The risk of seizure appears to increase with the ingested dose. In a review of 108 patients, seizures were seen in 18 percent of patients who ingested 600 mg to 1900 mg but in 47 percent of patients who ingested over 1900 mg [<a href="#rid48">48</a>]. In another case series, four out of five patients who ingested greater than 1400 mg developed seizures [<a href="#rid52">52</a>]. The majority of citalopram-induced seizures are brief, self-limited, and unlikely to result in neurologic sequelae, although recurrent seizures may occur occasionally [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Escitalopram</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> is a racemic mixture of R- and S-citalopram; <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> is the pharmacologically active S-enantiomer and a more potent inhibitor of serotonin reuptake [<a href="#rid69">69,70</a>]. Escitalopram toxicity appears to mimic that of citalopram and consists primarily of serotonin toxicity and QTc interval prolongation. Compared with citalopram, escitalopram seems to have greater serotonergic toxicity and less cardiac toxicity [<a href="#rid70">70</a>]. (See <a class="local">'Citalopram'</a> above.)</p><p>No serious toxicities or fatalities due to overdose were reported in clinical trials of <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> efficacy [<a href="#rid71">71,72</a>]. However, postmarketing surveillance data includes reports of seizures, QTc prolongation, ventricular dysrhythmias, and serotonin toxicity, albeit without demonstration of a causal relationship [<a href="#rid71">71</a>]. There is a case report of an escitalopram ingestion causing both QRS and QTc widening that responded to bicarbonate and magnesium infusions [<a href="#rid73">73</a>]. Escitalopram appears to cause fewer seizures after overdose than does <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> [<a href="#rid74">74</a>].</p><p>In overdose, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> may cause serotonin toxicity, tachycardia, and QTc prolongation, but there are no reports of torsades de pointes [<a href="#rid71">71,75-81</a>]. A retrospective review of 79 escitalopram exposures found that significant serotonin toxicity (eg, hyperthermia) occurred in 15 percent of patients who ingested escitalopram only, while isolated serotonergic neuromuscular findings (eg, hyperreflexia) developed in as many as 46 percent. Tachycardia (42 percent), bradycardia (14 percent), and QTc interval abnormalities (14 percent) were also noted. Reviews of poison center data have noted similar toxicity in addition to somnolence, vomiting, and tremors [<a href="#rid74">74,82</a>].</p><p class="headingAnchor" id="H3536904081"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of selective serotonin reuptake inhibitor (SSRI) poisoning is made clinically on the basis of the history and clinical presentation. Serum drug concentrations are generally not helpful in assessing SSRI poisoning and are not routinely available in most hospital clinical laboratories. Isolated SSRI ingestions generally produce only mild symptoms, although SSRI intoxication can infrequently produce serotonin toxicity, seizures, central nervous system (CNS) depression, or cardiac conduction abnormalities.</p><p class="headingAnchor" id="H18"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Significant toxicity in an isolated selective serotonin reuptake inhibitor (SSRI) ingestion is unlikely. If a patient appears sick or comatose, poisoning with a coingestant or an underlying non-toxicologic condition is more likely to be responsible. Diagnosis of the poisoned patient and comatose patient are reviewed separately. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a> and  <a class="medical medical_review" href="/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a> and  <a class="medical medical_review" href="/d/html/5104.html" rel="external">"Stupor and coma in adults"</a> and  <a class="medical medical_review" href="/d/html/6225.html" rel="external">"Evaluation of stupor and coma in children"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">LABORATORY EVALUATION</span><span class="headingEndMark"> — </span>Specific serum drug concentrations are generally not helpful in assessing or managing selective serotonin reuptake inhibitor (SSRI) ingestions. As examples, one study of antidepressant overdose found no correlation between <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> levels and mental status, while a study of <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> overdose found no correspondence between drug levels and symptom severity [<a href="#rid21">21,44</a>].</p><p>In the setting of SSRI ingestion, routine laboratory evaluation should be targeted at possible coingestants and should include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick glucose to rule out hypoglycemia as the cause of any alteration in mental status</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> and salicylate concentrations to rule out these common coingestions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol concentration; ethanol coingestion is associated with more severe toxicity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (ECG) to rule out conduction system poisoning by drugs that effect the QRS or corrected QT (QTc) intervals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum bicarbonate to screen for metabolic acidosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in women of childbearing age</p><p></p><p>In patients who develop serotonin syndrome with increased muscular tone or hyperthermia, the following laboratory information should be obtained:</p><p class="bulletIndent1"><span class="glyph">●</span>Creatine kinase and urine myoglobin to evaluate for rhabdomyolysis (see  <a class="medical medical_review" href="/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine to assess for kidney damage</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum aminotransferase concentrations to assess for liver injury</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation studies (ie, activated partial thromboplastin time [aPTT], prothrombin time [PT], international normalized ratio [INR], platelet count, D-dimer) to assess for disseminated intravascular coagulation (see  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous or arterial blood gas to assess for metabolic acidosis</p><p></p><p class="headingAnchor" id="H20"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>A summary table to facilitate emergency management of selective serotonin reuptake inhibitor (SSRI) poisoning is provided  (<a class="graphic graphic_table graphicRef82567" href="/d/graphic/82567.html" rel="external">table 1</a>). Since most SSRI ingestions develop minimal or no toxicity, the broad goal of management should be to provide supportive care and to minimize potentially unneeded and harmful interventions (see  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>). Serotonin agonists, such as <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">meperidine</a>, must be avoided in patients with SSRI ingestions or in those who have serotonin toxicity so as not to precipitate worse serotonergic manifestations. Most patients with SSRI ingestions have good outcomes with supportive care alone. Victims of minor, accidental exposures that are asymptomatic can be observed at home.</p><p class="headingAnchor" id="H21"><span class="h2">Airway, breathing, and circulation</span><span class="headingEndMark"> — </span>The airway should be secured with tracheal intubation in patients who are obtunded and cannot protect their airway. Hypoventilation, hypoperfusion, and unstable dysrhythmias must be addressed early according to standard advanced cardiac life support (ACLS) protocols. (See  <a class="medical medical_review" href="/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a>.) </p><p>For wide QRS complex tachycardia, <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> boluses can be given, followed by a bicarbonate infusion if there is subsequent narrowing of the QRS complex. (See  <a class="medical medical_review" href="/d/html/295.html" rel="external">"Tricyclic antidepressant poisoning", section on 'Sodium bicarbonate for cardiac toxicity'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Seizures typically respond to treatment with benzodiazepines such as <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> or <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>.</p><p class="headingAnchor" id="H23"><span class="h2">Role of decontamination</span><span class="headingEndMark"> — </span>In a patient who presents within one to two hours of an SSRI ingestion, we suggest administering a single dose of activated charcoal (AC) for gastrointestinal decontamination. The typical dose is 50 g orally in adults and 1 g/kg orally in children. Given the typical benign course of SSRI ingestions, AC should not be forced into a patient (such as via nasogastric tube) if they are refusing to drink it. Contraindications to AC include altered mental status and vomiting. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. However, tracheal intubation should not be performed solely for the purpose of giving charcoal. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p>The greatest benefit from AC decontamination occurs if given within one to two hours following the ingestion [<a href="#rid83">83</a>]. In a pharmacokinetic study of <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> overdose, a single dose of AC was found to increase clearance even up to four hours after ingestion [<a href="#rid84">84</a>]. In retrospective observational studies, a single dose of AC was associated with a lower rate of corrected QT (QTc) interval prolongation in <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> overdose [<a href="#rid85">85,86</a>].</p><p>Due to the rapid absorption of SSRIs, there is no role for multiple-dose AC or AC additives such as <a class="drug drug_general" data-topicid="9580" href="/d/drug information/9580.html" rel="external">magnesium citrate</a> or <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Multidose activated charcoal'</a>.)</p><p>There is no role for extracorporeal removal techniques such as hemodialysis because SSRIs are highly bound to serum proteins. (See  <a class="medical medical_review" href="/d/html/325.html" rel="external">"Enhanced elimination of poisons"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Serotonin syndrome (serotonin toxicity)</span><span class="headingEndMark"> — </span>Patients who develop serotonin toxicity are treated with supportive care, discontinuation of the offending agent, and, depending upon the severity of illness, a serotonin antagonist such as <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a>. Severe cases of serotonin syndrome that develop muscular rigidity and a core temperature greater than 41ºC must be treated aggressively with neuromuscular paralysis, tracheal intubation, and external cooling to prevent complications. A complete discussion of serotonin syndrome is found elsewhere. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">QTc interval prolongation</span><span class="headingEndMark"> — </span>All patients with SSRI ingestion and a prolonged QTc interval should be placed on a cardiac monitor and have <strong>serial</strong> electrocardiograms (ECGs) to be certain the interval is not continuing to lengthen. A reasonable approach is to perform a repeat ECG after one hour if the ingested agent may cause QRS prolongation, and again after four to six hours if concern for QTc prolongation persists. During this time, the patient should remain on a cardiac monitor to exclude the development of dysrhythmias, as ECGs only help determine the predisposition for a dysrhythmia.</p><p>A prolonged QTc interval predisposes to torsade de pointes, an intermittent ventricular dysrhythmia that can, albeit rarely, degenerate into potentially life-threatening monomorphic ventricular tachycardia or fibrillation. If on any subsequent ECG the QTc is longer than previous, the patient should remain on a cardiac monitor and another ECG performed in four to six hours. This is especially important for agents that have cardiotoxic metabolites, such as <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>. (See <a class="local">'Citalopram'</a> above.)</p><p>If the QTc interval is significantly prolonged (greater than 560 msec) and other concerning signs are present (eg, frequent premature ventricular contractions) or magnesium therapy is instituted, serial ECGs should be continued. As the QTc interval narrows, ECGs can be obtained every four to eight hours until the interval normalizes (less than 440 msec). Patients who will not be admitted should have a final ECG prior to discharge that demonstrates normal intervals.</p><p>Warning signs indicating an increased risk of torsade de pointes (torsades) include: a QTc interval greater than 560 msec, previous history of torsades, bradycardia, increased frequency and complexity of premature ventricular complexes/contractions (PVCs; also referred to as premature ventricular beats or premature ventricular depolarizations), or a PVC falling on the T-wave [<a href="#rid87">87</a>]. Magnesium therapy to prevent torsades should be given to patients with any of these findings. The dose of <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> in adults is 2 g over two minutes, which can be repeated after 10 to 15 minutes if the rhythm is not terminated. If there is clinical effect, a magnesium infusion at a rate of 2 to 10 mg/minute may be helpful until the QTc interval is less than 500 msec.</p><p class="headingAnchor" id="H26"><span class="h2">Observation</span><span class="headingEndMark"> — </span>Patients can be referred to psychiatry after a four- to six-hour observation period if they are asymptomatic and have not developed ECG changes, particularly significant prolongation of the QTc interval. Massive ingestions (ie, those greater than 150 times the daily dose of the SSRI) should be admitted for 24 hours of cardiac monitoring, since these are at greatest risk for severe toxicity.</p><p>Because <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> potentially have a cardiotoxic metabolite, patients with these ingestions should receive an ECG at least six hours after their ingestion. If these patients have any significant interval prolongation, have a progressively increasing QTc interval, or have experienced a dysrhythmia, they should be admitted for cardiac monitoring and observation until their ECG intervals normalize.</p><p class="headingAnchor" id="H28"><span class="h1">PEDIATRIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>Pediatric ingestions of selective serotonin reuptake inhibitors (SSRIs) are generally well tolerated [<a href="#rid17">17</a>]. <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> caused either no or minimal symptoms (sleepiness, hyperactivity, and diarrhea) in 20 pediatric ingestions in one prospective study [<a href="#rid19">19</a>]. A retrospective poison center review identified 120 cases of isolated fluoxetine ingestions in children less than six years of age; 116 were asymptomatic, three had emesis, and one was sedated [<a href="#rid88">88</a>]. Although most fluoxetine ingestions are reported to be benign, intentional large ingestions can lead to serotonin toxicity [<a href="#rid89">89</a>]. <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> and <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> also produce minimal toxicity. Several studies noted that most patients are asymptomatic; those that are symptomatic most commonly manifest central nervous system (CNS) stimulation, drowsiness, dizziness, vomiting, or sinus tachycardia [<a href="#rid39">39,42,90,91</a>].</p><p>Few data exist on the safety of <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> in pediatric ingestions. There is one case report of a child of four years requiring intubation for CNS depression and vasopressor support for hypotension following a 400 mg ingestion [<a href="#rid92">92</a>]. There are several reports of <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> and fluvoxamine ingestions causing serotonin toxicity in children [<a href="#rid93">93-95</a>].</p><p>Case reports suggest that <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a> can be used to treat serotonin toxicity in children [<a href="#rid93">93</a>]. The pediatric dose of cyproheptadine is 0.25 mg/kg per day divided twice or three times daily up to a maximum dose of 12 mg [<a href="#rid96">96</a>].</p><p>The relationship between SSRIs and increased risk of suicide among pediatric patients is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p>Maternal <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> and <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> use has been associated with a hyperserotonergic state in neonates and in breast-feeding infants [<a href="#rid97">97,98</a>]. In newborns, serotonergic symptoms can manifest as fever, somnolence, jitteriness, irritability, tremors, and a hyperactive Moro (ie, startle) reflex. (See  <a class="medical medical_review" href="/d/html/89067.html" rel="external">"Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors", section on 'Selective serotonin reuptake inhibitors'</a>.)</p><p class="headingAnchor" id="H13369077"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2352299301"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H3084787505"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H532830208"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87578.html" rel="external">"Patient education: Serotonin syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Selective serotonin reuptake inhibitors (SSRIs) are generally well tolerated in overdose and are much safer than other antidepressant medications such as tricyclic antidepressants (TCAs). Toxicity is most commonly due to co-ingestants. Victims of intentional ingestions often develop greater toxicity than accidental exposures. A summary table to facilitate the emergency management of SSRI poisoning is provided  (<a class="graphic graphic_table graphicRef82567" href="/d/graphic/82567.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of overdose</strong> – Most SSRI ingestions develop minimal or no toxicity. SSRIs rarely produce fatality or serious sequelae, mainly due to their wide therapeutic window: Ingestion of up to 30 times the daily dose typically produces minor or no symptoms, while ingestion of 50 to 75 times the daily dose can cause vomiting, mild central nervous system (CNS) depression, or tremor. Most fatalities are reported with either extremely large doses (greater than 150 times the daily dose) or with the presence of co-ingestants such as ethanol, benzodiazepines, or TCAs. (See <a class="local">'Clinical features of overdose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serotonin syndrome (serotonin toxicity)</strong> – This complication  (<a class="graphic graphic_algorithm graphicRef138424" href="/d/graphic/138424.html" rel="external">algorithm 1</a>) rarely occurs after isolated SSRI ingestions, but severe episodes can occur following either a mixed serotonergic ingestion or changes made in therapeutic SSRI dosing. Serotonin toxicity caused by isolated SSRI ingestion tends not be severe. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dysrhythmias and seizures</strong> – Although rare, SSRI ingestions can cause seizures or prolonged electrocardiogram (ECG) intervals, predisposing to dysrhythmias. <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> are most likely to cause abnormal cardiac conduction. (See <a class="local">'Citalopram'</a> above and <a class="local">'Escitalopram'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation</strong> – Specific serum drug concentrations are generally not helpful in assessing or managing SSRI ingestions. Routine laboratory evaluation should be targeted at possible co-ingestants such as <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, salicylates, and ethanol. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Assess and stabilize airway, breathing, and circulation. Since toxicity tends to be mild, the broad goal of management should be to provide supportive care and to minimize potentially unneeded and harmful interventions. A summary table to facilitate the emergency management of SSRI poisoning is provided  (<a class="graphic graphic_table graphicRef82567" href="/d/graphic/82567.html" rel="external">table 1</a>). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of gastrointestinal decontamination</strong> – In a patient who presents within one to two hours of an SSRI ingestion, we suggest administering a single dose of activated charcoal (AC) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The typical dose is 50 g in adults and 1 g/kg in children. Charcoal should be withheld in patients who are sedated and may not be able to protect their airway unless tracheal intubation is performed first. Tracheal intubation should not be performed solely for the purpose of giving charcoal. (See <a class="local">'Role of decontamination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizures</strong> – Seizures typically respond to treatment with benzodiazepines such as <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> or <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>. (See <a class="local">'Seizures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Widened QTc interval</strong> –<strong> </strong>All patients with SSRI ingestion and a prolonged QTc interval should have <strong>serial</strong> ECGs to be certain the interval is not continuing to lengthen and be observed on a cardiac monitor. (See <a class="local">'QTc interval prolongation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Spyker DA, et al. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila) 2018; 56:1213.</a></li><li><a class="nounderline abstract_t">Townsend E, Hawton K, Harriss L, et al. Substances used in deliberate self-poisoning 1985-1997: trends and associations with age, gender, repetition and suicide intent. Soc Psychiatry Psychiatr Epidemiol 2001; 36:228.</a></li><li><a class="nounderline abstract_t">Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol (Phila) 2022; 60:143.</a></li><li><a class="nounderline abstract_t">Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112.</a></li><li class="breakAll">Prozac Package Insert 2005. Eli Lilly and Company (www.lilly.com).</li><li><a class="nounderline abstract_t">Graudins A, Dowsett RP, Liddle C. The toxicity of antidepressant poisoning: is it changing? A comparative study of cyclic and newer serotonin-specific antidepressants. Emerg Med (Fremantle) 2002; 14:440.</a></li><li><a class="nounderline abstract_t">Mason J, Freemantle N, Eccles M. Fatal toxicity associated with antidepressant use in primary care. Br J Gen Pract 2000; 50:366.</a></li><li><a class="nounderline abstract_t">Stoner SC, Marken PA, Watson WA, et al. Antidepressant overdoses and resultant emergency department services: the impact of SSRIs. Psychopharmacol Bull 1997; 33:667.</a></li><li><a class="nounderline abstract_t">Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310:221.</a></li><li><a class="nounderline abstract_t">Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325:1332.</a></li><li><a class="nounderline abstract_t">Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42:277.</a></li><li><a class="nounderline abstract_t">Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59 Suppl 15:42.</a></li><li><a class="nounderline abstract_t">Reichert C, Reichert P, Monnet-Tschudi F, et al. Seizures after single-agent overdose with pharmaceutical drugs: analysis of cases reported to a poison center. Clin Toxicol (Phila) 2014; 52:629.</a></li><li><a class="nounderline abstract_t">Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in the elderly due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Geriatr Psychiatry Neurol 2003; 16:160.</a></li><li><a class="nounderline abstract_t">Movig KL, Leufkens HG, Lenderink AW, et al. Association between antidepressant drug use and hyponatraemia: a case-control study. Br J Clin Pharmacol 2002; 53:363.</a></li><li><a class="nounderline abstract_t">Nahshoni E, Weizman A, Shefet D, Pik N. A case of hyponatremia associated with escitalopram. J Clin Psychiatry 2004; 65:1722.</a></li><li><a class="nounderline abstract_t">Spiller HA, Morse S, Muir C. Fluoxetine ingestion: a one year retrospective study. Vet Hum Toxicol 1990; 32:153.</a></li><li><a class="nounderline abstract_t">Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46:59.</a></li><li><a class="nounderline abstract_t">Borys DJ, Setzer SC, Ling LJ, et al. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992; 10:115.</a></li><li><a class="nounderline abstract_t">Chiang WK, Ford MK, Wax PM, et al. Prospective evaluation of fluoxetine ingestions. Vet Hum Toxicol 1990; 32:348.</a></li><li><a class="nounderline abstract_t">Phillips S, Brent J, Kulig K, et al. Fluoxetine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses. The Antidepressant Study Group. J Emerg Med 1997; 15:439.</a></li><li><a class="nounderline abstract_t">Moore JL, Rodriguez R. Toxicity of fluoxetine in overdose. Am J Psychiatry 1990; 147:1089.</a></li><li><a class="nounderline abstract_t">Compton R, Spiller HA, Bosse GM. Fatal fluoxetine ingestion with postmortem blood concentrations. Clin Toxicol (Phila) 2005; 43:277.</a></li><li><a class="nounderline abstract_t">Kincaid RL, McMullin MM, Crookham SB, Rieders F. Report of a fluoxetine fatality. J Anal Toxicol 1990; 14:327.</a></li><li><a class="nounderline abstract_t">Rohrig TP, Prouty RW. Fluoxetine overdose: a case report. J Anal Toxicol 1989; 13:305.</a></li><li><a class="nounderline abstract_t">Gross R, Dannon PN, Lepkifker E, et al. Generalized seizures caused by fluoxetine overdose. Am J Emerg Med 1998; 16:328.</a></li><li><a class="nounderline abstract_t">Braitberg G, Curry SC. Seizure after isolated fluoxetine overdose. Ann Emerg Med 1995; 26:234.</a></li><li><a class="nounderline abstract_t">Riddle MA, Brown N, Dzubinski D, et al. Fluoxetine overdose in an adolescent. J Am Acad Child Adolesc Psychiatry 1989; 28:587.</a></li><li><a class="nounderline abstract_t">Graudins A, Vossler C, Wang R. Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy. Am J Emerg Med 1997; 15:501.</a></li><li><a class="nounderline abstract_t">Cooper GL. The safety of fluoxetine--an update. Br J Psychiatry Suppl 1988; :77.</a></li><li><a class="nounderline abstract_t">Gardner SF, Rutherford WF, Munger MA, Panacek EA. Drug-induced supraventricular tachycardia: a case report of fluoxetine. Ann Emerg Med 1991; 20:194.</a></li><li><a class="nounderline abstract_t">Roberge RJ, Martin TG. Mixed fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med 1994; 23:586.</a></li><li><a class="nounderline abstract_t">McAnally LE, Threlkeld KR, Dreyling CA. Case report of a syncopal episode associated with fluoxetine. Ann Pharmacother 1992; 26:1090.</a></li><li><a class="nounderline abstract_t">Ahmed I, Dagincourt PG, Miller LG, Shader RI. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 1993; 38:62.</a></li><li><a class="nounderline abstract_t">Hofman, M, Liu, JK. Conduction abnormality and ventricular tachyarrhythmia associated with fluoxetine overdose (abstract). Vet Hum Toxicol 1994; 36:371.</a></li><li><a class="nounderline abstract_t">Appleby M, Mbewu A, Clarke B. Fluoxetine and ventricular torsade--is there a link? Int J Cardiol 1995; 49:178.</a></li><li><a class="nounderline abstract_t">Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991; 6 Suppl 2:47.</a></li><li><a class="nounderline abstract_t">Caracci G. Unsuccessful suicide attempt by sertraline overdose. Am J Psychiatry 1994; 151:147.</a></li><li><a class="nounderline abstract_t">Klein-Schwartz W, Anderson B. Analysis of sertraline-only overdoses. Am J Emerg Med 1996; 14:456.</a></li><li><a class="nounderline abstract_t">Lau GT, Horowitz BZ. Sertraline overdose. Acad Emerg Med 1996; 3:132.</a></li><li><a class="nounderline abstract_t">Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53 Suppl:61.</a></li><li><a class="nounderline abstract_t">Myers LB, Dean BS, Krenelok EP. Paroxetine (Paxil): overdose assessment of a new selective serotonin reuptake inhibitor (abstract). Vet Hum Toxicol 1994; 36:370.</a></li><li><a class="nounderline abstract_t">Tonks A. Withdrawal from paroxetine can be severe, warns FDA. BMJ 2002; 324:260.</a></li><li><a class="nounderline abstract_t">Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993; 21:197.</a></li><li><a class="nounderline abstract_t">Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993; 54:146.</a></li><li><a class="nounderline abstract_t">Tan JY, Levin GM. Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 1999; 19:675.</a></li><li><a class="nounderline abstract_t">Personne M, Sjöberg G, Persson H. Citalopram overdose--review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997; 35:237.</a></li><li><a class="nounderline abstract_t">Personne M, Persson H, Sjöberg E. Citalopram toxicity. Lancet 1997; 350:518.</a></li><li><a class="nounderline abstract_t">Bin Salih S, Al Qahtani M, Al Anazi T, et al. Metabolic acidosis and generalized seizures secondary to citalopram overdose: a case report. J Clin Pharm Ther 2010; 35:479.</a></li><li class="breakAll">Celexa Package Insert (2005). Forest Pharmaceuticals, http://www.frx.com/pi/celexa_pi.pdf (Accessed March 23, 2006).</li><li><a class="nounderline abstract_t">Rasmussen SL, Overø KF, Tanghøj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999; 19:407.</a></li><li><a class="nounderline abstract_t">Grundemar L, Wohlfart B, Lagerstedt C, et al. Symptoms and signs of severe citalopram overdose. Lancet 1997; 349:1602.</a></li><li><a class="nounderline abstract_t">Kelly CA, Dhaun N, Laing WJ, et al. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004; 42:67.</a></li><li><a class="nounderline abstract_t">Catalano G, Catalano MC, Epstein MA, Tsambiras PE. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol 2001; 24:158.</a></li><li><a class="nounderline abstract_t">Engebretsen KM, Harris CR, Wood JE. Cardiotoxicity and late onset seizures with citalopram overdose. J Emerg Med 2003; 25:163.</a></li><li><a class="nounderline abstract_t">Meuleman C, Jourdain P, Bellorini M, et al. [Citalopram and Torsades de Pointes. A case report]. Arch Mal Coeur Vaiss 2001; 94:1021.</a></li><li><a class="nounderline abstract_t">Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008; 4:101.</a></li><li><a class="nounderline abstract_t">Fayssoil A, Issi J, Guerbaa M, et al. Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris) 2011; 60:165.</a></li><li><a class="nounderline abstract_t">de Gregorio C, Morabito G, Cerrito M, et al. Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. Int J Cardiol 2011; 148:226.</a></li><li><a class="nounderline abstract_t">Blaschke D, Parwani AS, Huemer M, et al. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry 2007; 40:294.</a></li><li><a class="nounderline abstract_t">Kanjanauthai S, Kanluen T, Chareonthaitawee P. Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol 2008; 131:e33.</a></li><li><a class="nounderline abstract_t">Kraai EP, Seifert SA. Citalopram Overdose: a Fatal Case. J Med Toxicol 2015; 11:232.</a></li><li><a class="nounderline abstract_t">Snider RD. Case report: left bundle branch block--a rare complication of citalopram overdose. J S C Med Assoc 2001; 97:380.</a></li><li><a class="nounderline abstract_t">Rothenhäusler HB, Hoberl C, Ehrentrout S, et al. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry 2000; 33:150.</a></li><li><a class="nounderline abstract_t">Cuenca PJ, Holt KR, Hoefle JD. Seizure secondary to citalopram overdose. J Emerg Med 2004; 26:177.</a></li><li><a class="nounderline abstract_t">Liotier J, Coudoré F. Drug monitoring of a case of citalopram overdosage. Drug Chem Toxicol 2011; 34:420.</a></li><li><a class="nounderline abstract_t">Oström M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet 1996; 348:339.</a></li><li><a class="nounderline abstract_t">Zoofaghari S, Wong A, Kiarasi P, Gheshlaghi F. Massive Citalopram Overdose Associated with Recurrent Seizures and Bilateral Shoulder Dislocations. J Res Pharm Pract 2020; 9:161.</a></li><li><a class="nounderline abstract_t">Escitalopram (lexapro) for depression. Med Lett Drugs Ther 2002; 44:83.</a></li><li><a class="nounderline abstract_t">van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009; 54:404.</a></li><li><a class="nounderline abstract_t">Barnett AK, Brush DE, Schroeder W. The pharmacology and toxicology of escitalopram. Int J Med Toxicol 2003; 6:14.</a></li><li class="breakAll">Lexapro Package Insert (2005), Forest Pharmaceuticals, http://www.frx.com/pi/lexapro_pi.pdf (Accessed March 23, 2006).</li><li><a class="nounderline abstract_t">Schreffler SM, Marraffa JM, Stork CM, Mackey J. Sodium channel blockade with QRS widening after an escitalopram overdose. Pediatr Emerg Care 2013; 29:998.</a></li><li><a class="nounderline abstract_t">Yilmaz Z, Ceschi A, Rauber-Lüthy C, et al. Escitalopram causes fewer seizures in human overdose than citalopram. Clin Toxicol (Phila) 2010; 48:207.</a></li><li><a class="nounderline abstract_t">Abstracts of the North American Congress of Clinical Toxicology Annual Meeting. September 4-9, 2003. Chicago, Illinois, USA. J Toxicol Clin Toxicol 2003; 41:641.</a></li><li><a class="nounderline abstract_t">Ginsburg BY, Wiener SW, Henderson KJ, et al. QTc interval prolongation associated with escitalopram overdose (abstract #174). J Toxicol Clin Toxicol 2005; 43:502.</a></li><li><a class="nounderline abstract_t">Scharko AM, Schumacher J. Prolonged QTc interval in a 14-year-old girl with escitalopram overdose. J Child Adolesc Psychopharmacol 2008; 18:297.</a></li><li><a class="nounderline abstract_t">Yuksel FV, Tuzer V, Goka E. Escitalopram intoxication. Eur Psychiatry 2005; 20:82.</a></li><li><a class="nounderline abstract_t">Olsen DG, Dart RC, Robinett M. Severe serotonin syndrome from escitalopram overdose. J Toxicol Clin Toxicol 2004; 42:744.</a></li><li><a class="nounderline abstract_t">Huska MT, Catalano G, Catalano MC. Serotonin syndrome associated with the use of escitalopram. CNS Spectr 2007; 12:270.</a></li><li><a class="nounderline abstract_t">Lindgren, KN, et al. Escitalopram, a review of adverse effects in overdose reported to select regional poison centers (abstract #41). J Toxicol Clin Toxicol 2003; 41:658.</a></li><li><a class="nounderline abstract_t">Forrester MB. Escitalopram ingestions reported to Texas poison control centers, 2002-2005. Hum Exp Toxicol 2007; 26:473.</a></li><li><a class="nounderline abstract_t">Chyka PA, Seger D, Krenzelok EP, et al. Position paper: Single-dose activated charcoal. Clin Toxicol 2005; 43:61.</a></li><li><a class="nounderline abstract_t">Cooper JM, Duffull SB, Saiao AS, Isbister GK. The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. Br J Clin Pharmacol 2015; 79:307.</a></li><li><a class="nounderline abstract_t">Isbister GK, Friberg LE, Stokes B, et al. Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med 2007; 50:593.</a></li><li><a class="nounderline abstract_t">van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. Br J Clin Pharmacol 2012; 73:402.</a></li><li><a class="nounderline abstract_t">Keren A, Tzivoni D. Torsades de pointes: prevention and therapy. Cardiovasc Drugs Ther 1991; 5:509.</a></li><li><a class="nounderline abstract_t">Baker SD, Morgan DL. Fluoxetine exposures: are they safe for children? Am J Emerg Med 2004; 22:211.</a></li><li><a class="nounderline abstract_t">Yildiz R, Gumus S, Nur Ozkul S, Uysalol M. Serotonin syndrome in an adolescent as a result of suicide with fluoxetine. Asia Pac J Med Tox 2022; 11:37.</a></li><li><a class="nounderline abstract_t">Myers LB, Dean BS, Krenzelok EP. Sertraline (Zoloft): a pediatric overdose approach (abstract). Vet Human Toxicol 1994; 36:361.</a></li><li><a class="nounderline abstract_t">Myers LB, Krenzelok EP. Paroxetine (Paxil) overdose: a pediatric focus. Vet Hum Toxicol 1997; 39:86.</a></li><li><a class="nounderline abstract_t">Fraser J, South M. Life-threatening fluvoxamine overdose in a 4-year-old child. Intensive Care Med 1999; 25:548.</a></li><li><a class="nounderline abstract_t">Horowitz BZ, Mullins ME. Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion. Pediatr Emerg Care 1999; 15:325.</a></li><li><a class="nounderline abstract_t">Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med 1994; 23:1371.</a></li><li><a class="nounderline abstract_t">Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med 1999; 33:457.</a></li><li class="breakAll">Mosby. Mosby's Drug Consult: A Comprehensive Reference for Brand and Generic Prescription Drugs, Mosby, Philadelphia 2002.</li><li><a class="nounderline abstract_t">Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr (Phila) 2001; 40:681.</a></li><li><a class="nounderline abstract_t">Isbister GK, Dawson A, Whyte IM, et al. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001; 85:F147.</a></li></ol></div><div id="topicVersionRevision">Topic 297 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30576252" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11515700" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Substances used in deliberate self-poisoning 1985-1997: trends and associations with age, gender, repetition and suicide intent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34806513" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784664" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784664" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12534489" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The toxicity of antidepressant poisoning: is it changing? A comparative study of cyclic and newer serotonin-specific antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10897532" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fatal toxicity associated with antidepressant use in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9493477" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antidepressant overdoses and resultant emergency department services: the impact of SSRIs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7866123" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Relative mortality from overdose of antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468481" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15362595" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9786310" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : SSRI safety in overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24844578" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Seizures after single-agent overdose with pharmaceutical drugs: analysis of cases reported to a poison center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967059" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Paroxetine-induced hyponatremia in the elderly due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966666" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Association between antidepressant drug use and hyponatraemia: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641882" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A case of hyponatremia associated with escitalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2327065" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fluoxetine ingestion: a one year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3156126" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The side effect profile and safety of fluoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586402" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acute fluoxetine overdose: a report of 234 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prospective evaluation of fluoxetine ingestions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9279692" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fluoxetine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses. The Antidepressant Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375446" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Toxicity of fluoxetine in overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16035204" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fatal fluoxetine ingestion with postmortem blood concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2263071" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Report of a fluoxetine fatality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2693835" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fluoxetine overdose: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596448" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Generalized seizures caused by fluoxetine overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7618791" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Seizure after isolated fluoxetine overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2788642" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fluoxetine overdose in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9270390" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3074869" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The safety of fluoxetine--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996805" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Drug-induced supraventricular tachycardia: a case report of fluoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135440" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mixed fluoxetine/loxapine overdose and atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1421672" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Case report of a syncopal episode associated with fluoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8448725" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Possible interaction between fluoxetine and pimozide causing sinus bradycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Conduction abnormality and ventricular tachyarrhythmia associated with fluoxetine overdose (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7628890" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fluoxetine and ventricular torsade--is there a link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1806630" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Toleration and safety of sertraline: experience worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8267114" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Unsuccessful suicide attempt by sertraline overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8765108" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Analysis of sertraline-only overdoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808373" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sertraline overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1531828" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The safety profile of paroxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Paroxetine (Paxil): overdose assessment of a new selective serotonin reuptake inhibitor (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11823353" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Withdrawal from paroxetine can be severe, warns FDA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7906658" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute fluvoxamine poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8486592" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The abrupt discontinuation of fluvoxamine in patients with panic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391413" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Citalopram in the treatment of depression and other potential uses in psychiatry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9140316" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Citalopram overdose--review of cases treated in Swedish hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9274602" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Citalopram toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20831549" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Metabolic acidosis and generalized seizures secondary to citalopram overdose: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20831549" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Metabolic acidosis and generalized seizures secondary to citalopram overdose: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10505582" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cardiac safety of citalopram: prospective trials and retrospective analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174567" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Symptoms and signs of severe citalopram overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15083939" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparative toxicity of citalopram and the newer antidepressants after overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11391127" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : QTc interval prolongation associated with citalopram overdose: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902002" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cardiotoxicity and late onset seizures with citalopram overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11603066" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : [Citalopram and Torsades de Pointes. A case report].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18570170" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21295285" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Torsade de pointes induced by citalopram and amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540606" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18030657" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Torsade de pointes during combined treatment with risperidone and citalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919753" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Citalopram induced torsade de pointes, a rare life threatening side effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25326372" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Citalopram Overdose: a Fatal Case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11584496" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Case report: left bundle branch block--a rare complication of citalopram overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10958266" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14980340" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Seizure secondary to citalopram overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21846175" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Drug monitoring of a case of citalopram overdosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8709713" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fatal overdose with citalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33489987" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Massive Citalopram Overdose Associated with Recurrent Seizures and Bilateral Shoulder Dislocations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360121" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Escitalopram (lexapro) for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556032" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinical and ECG effects of escitalopram overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The pharmacology and toxicology of escitalopram</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The pharmacology and toxicology of escitalopram</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24201980" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sodium channel blockade with QRS widening after an escitalopram overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20170390" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Escitalopram causes fewer seizures in human overdose than citalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Chicago, Illinois, USA</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : QTc interval prolongation associated with escitalopram overdose (abstract #174)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18582186" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prolonged QTc interval in a 14-year-old girl with escitalopram overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642453" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Escitalopram intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Severe serotonin syndrome from escitalopram overdose</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426664" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Serotonin syndrome associated with the use of escitalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Escitalopram, a review of adverse effects in overdose reported to select regional poison centers (abstract #41)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698942" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Escitalopram ingestions reported to Texas poison control centers, 2002-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Position paper: Single-dose activated charcoal</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25155462" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The pharmacokinetics of sertraline in overdose and the effect of activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17719135" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Activated charcoal decreases the risk of QT prolongation after citalopram overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883384" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1854660" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Torsades de pointes: prevention and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138960" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Fluoxetine exposures: are they safe for children?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Serotonin syndrome in an adolescent as a result of suicide with fluoxetine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Sertraline (Zoloft): a pediatric overdose approach (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9080633" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Paroxetine (Paxil) overdose: a pediatric focus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401959" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Life-threatening fluvoxamine overdose in a 4-year-old child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10532660" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8198316" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Sertraline intoxication in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10092727" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Serotonin syndrome in a child after a single dose of fluvoxamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10092727" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Serotonin syndrome in a child after a single dose of fluvoxamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11771923" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Fluoxetine toxicity in a breastfed infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561552" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
